Results 131 to 140 of about 2,492,664 (191)
Drug Design, Development and TherapySarah-Jane Martin,1,2 Melanie Guenette,1 Jiwon Oh1 1Division of Neurology, Department of Medicine, St Michael’s Hospital, Toronto, Canada; 2University of Glasgow, Glasgow, UKCorrespondence: Jiwon Oh, Email jiwon.oh@unityhealth.toAbstract: B cells are ...
Martin SJ, Guenette M, Oh J
doaj
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
, 2015 Bispecific antibodies and antibody fragments in various formats have been explored as a means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been reported with molecules such as the anti-CD19/CD3 bispecific T cell ...
+16 additional authors +10 more
core +1 more source
, 1999 Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission.
Vartholomatos, G. +5 more
core
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 11, November 2026.Betaine helps to restore the dysfunctional communication between oxidative stress and inflammation, and it also improves demyelination in cuprizone‐induced demyelinating disease within the cerebral cortex. ABSTRACT Cortical grey matter pathology manifests early demyelinating diseases and is a primary driver of permanent neurological impairment.
Yara M. Said +4 more
wiley +1 more source
Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: A case report [PDF]
, 2006 Idiopathic thrombocytopenic purpura (ITP) is an immune-mediated disorder characterized by accelerated and premature destruction of platelets by reticuloendothelial system. CD20, a transmembrane B-cell-specific antigen, is a potential target for treatment
Latifzadeh, S.Z., Entezari, V.
core
MedComm, Volume 7, Issue 11, November 2026.Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He +4 more
wiley +1 more source
Early Diagnosis and Successful Treatment of Acute Antibody-Mediated Rejection of a Renal Transplant
, 2011 Antibody-mediated rejection is a delicate situation. it rarely occurs but when it does, it usually results in graft dysfunction and frequently, graft loss.
YANG, YA-WEN;LIN, WEI-CHOU;WU, MING-SHIOU;LEE, PO-HUANG;TSAI, MENG-KUN +1 more
core
Respirology Case Reports, Volume 14, Issue 11, November 2026.Patients with malignant lymphoma receiving anti‐CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID‐19). We report three cases of persistent COVID‐19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir‐based treatment. Switching to an antiviral
Mika Horie +12 more
wiley +1 more source
Multiple Sclerosis and Viruses: « Liaisons Dangereuses »
Reviews in Medical Virology, Volume 36, Issue 6, November 2026.ABSTRACT Multiple sclerosis (MS) is a complex, multifactorial neurodegenerative disease with an aetiology that is still partially elusive. Several risk factors are associated with MS development including genetic predisposition and various environmental stressors; however, recently, viral infections have gained significant attention as a crucial ...
Samanta Plavina +11 more
wiley +1 more source